Geoffrey Hackett

Geoffrey Hackett

Auto-generated profile, based on publicly available information

Geoffrey Hackett

School of Health and Life Sciences Aston University Birmingham UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in The Journal of Sexual Medicine
Verified
Journal Article
Open access
GHGeoff Hackett
Geoff Hackett
MKMichael Kirby
Michael Kirby
DEDavid Edwards
David Edwards
TJThomas Hugh Jones
Thomas Hugh Jones
KWKevan Wylie
Kevan Wylie
AMAsif Muneer
Asif Muneer
Background: Testosterone deficiency (TD) is an increasingly common problem with significant health implications, but its diagnosis and management can be challenging.Aim: To review the available literature on TD and provide evidence-based statements for UK clinical practice.Methods: Evidence was derived from Medline, EMBASE, and Cochrane searches on hypogonadism, testosterone (T) therapy, and cardiovascular safety from May 2005 to May 2015. Further searches continued until May 2017.Outcomes: To provide a guideline on diagnosing and managing TD, with levels of evidence and grades of recommendation, based on a critical review of the literature and consensus of the British Society of Sexual Medicine panel.Results: 25 statements are provided, relating to 5 key areas: screening, diagnosis, initiating T therapy, benefits and risks of T therapy, and follow-up. 7 statements are supported by level 1, 8 by level 2, 5 by level 3, and 5 by level 4 evidence.Clinical Implications: To help guide UK practitioners on effectively diagnosing and managing primary and age-related TD.Strengths and Limitations: A large amount of literature was carefully sourced and reviewed, presenting the best evidence available at the time. However, some statements provided are based on poor-quality evidence. This is a rapidly evolving area of research and recommendations are subject to change. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions and take personal values and preferences and individual circumstances into account. Many issues remain controversial, but in the meantime, clinicians need to manage patient needs and clinical expectations armed with the best clinical evidence and the multidisciplinary expert opinion available.Conclusion: Improving the diagnosis and management of TD in adult men should provide somatic, sexual, and psychological benefits and subsequent improvements in quality of life.

1 January 2023 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
GHGeoffrey Hackett
Geoffrey Hackett
MKMichael Kirby
Michael Kirby
RRRowland W. Rees
Rowland W. Rees
TJT. Hugh Jones
T. Hugh Jones
AMAsif Muneer
Asif Muneer
SRSudarshan Ramachandran
Sudarshan Ramachandran
Hackett G, et al. World J Mens Health. 2023 Feb;41:e33. https://doi.org/10.5534/wjmh.221027

14 September 2018 in BJU International
Verified
Journal Article
Closed access
PDF file
GHGeoffrey Hackett
Geoffrey Hackett
NCNigel Cole
Nigel Cole
AMAkhilesh Mulay
Akhilesh Mulay
RSRichard C. Strange
Richard C. Strange
SRSudarshan Ramachandran
Sudarshan Ramachandran

15 July 2022 in Androgens: Clinical Research and Therapeutics
Verified
Journal Article
Open access
DTDavid K. Twitchell
David K. Twitchell
MCMichael B. Christensen
Michael B. Christensen
GHGeoffrey Hackett
Geoffrey Hackett
AMAbraham Morgentaler
Abraham Morgentaler
FSFarid Saad
Farid Saad
APAlexander W. Pastuszak
Alexander W. Pastuszak
Although not universal, many epidemiological data sources signal that a higher proportion of males than females with confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections have adverse outcomes, such as intensive care unit (ICU) admission and death. Though likely multifactorial, the various hypotheses that have been proposed as underlying factors behind this trend are related to greater smoking prevalence among males, testosterone (T) deficiency causing an inflammatory storm, androgen-driven pathogenesis of SARS-CoV-2, a protective effect of estrogen in females, and inborn errors of cytokine immunity. This review aims at examining the evidence and at assessing the likelihood that the factors being investigated are contributory to the reported trend of male predominance of severe COVID-19 cases. Sources were obtained using the PubMed database and were selected based on their relevance to one of the primary hypotheses attempting to explain the strong male sex bias of severe SARS-CoV-2 infections. Emphasis was placed on meta-analyses and population-based studies. Sources are current through February 22, 2022. A severe COVID-19 case or outcome is defined in this review as a progression of the SARS-CoV-2 virus that results in either admission to an ICU for management of symptoms and clinical stabilization or which leads to death. Although the trend of male predominance of severe COVID-19 cases is likely multifactorial, the hypothesis of T deficiency causing an inflammatory storm has support from many studies with limited conflicting evidence. An inborn error in cytokine immunity is also well supported, but it needs more studies to add support to the hypothesis. The immunologic protective effect of estrogen is supported by multiple studies, but it also has conflicting evidence. It appears less likely that the trend is caused solely by an increased prevalence of smoking among males or an androgen-driven pathogenesis, based on the extent of conflicting evidence.

1 July 2019 in Sexual Medicine Reviews
Verified
Journal Article
Closed access
GHGeoffrey Hackett
Geoffrey Hackett
Up to 40% of men with type 2 diabetes (T2DM) and metabolic syndrome (MetS) have hypogonadotrophic hypogonadism (HH). Men with HH are at increased risk of cardiovascular (CV) and all-cause mortality, as well as of the development of incident T2DM. To review the current literature on the metabolic effects of testosterone therapy (TTh) in men with T2DM and MetS. We searched MEDLINE, Embase, and Cochrane Reviews for articles on T2DM, HH, testosterone deficiency, and CV and all-cause mortality published between May 2005 and July 2018, yielding 1817 articles, including 54 clinical trials and 32 randomized controlled trials (RCTs). The main outcomes were glycemic control, insulin resistance, lipid profile, and metabolic markers associated with increased CV risk. RCTs of TTh suggest significant benefits for sexual function, quality of life, glycemic control, insulin sensitivity, anemia, bone density, and fat and lean muscle mass that might be expected to translate into reduced long-term morbidity and mortality. Several longitudinal and observational studies suggest long-term sustained improvements in metabolic parameters and a trend toward reduced CV and all-cause mortality, especially in men at increased CV risk, such as those with T2DM and MetS. The greatest benefit is seen in those men treated with TTh to target levels and for longer durations. Meta-analyses of RCTs, rather than providing clarification, may have further confused the issue by including underpowered studies of inadequate duration, multiple therapy regimens, some obsolete or withdrawn, and built-in bias in terms of studies included or excluded from analysis. Hackett G. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome. Sex Med Rev 2019;7:476-490.

1 January 2019 in The World Journal of Men's Health
Verified
Journal Article
Open access
GHGeoffrey Hackett
Geoffrey Hackett
A third of men with type 2 diabetes (T2DM) have hypogonadotrophic hypogonadism (HH) and associated increased risk of cardiovascular and all-cause mortality. Men with HH are at increased risk of developing incident T2DM. We conducted MEDLINE, EMBASE, and COCHRANE reviews on T2DM, HH, testosterone deficiency, cardiovascular and all-cause mortality from May 2005 to October 2017, yielding 1,714 articles, 52 clinical trials and 32 randomized controlled trials (RCT). Studies with testosterone therapy suggest significant benefits in sexual function, quality of life, glycaemic control, anaemia, bone density, fat, and lean muscle mass. Meta-analyses of RCT, rather than providing clarification, have further confused the issue by including under-powered studies of inadequate duration, multiple regimes, some discontinued, and inbuilt bias in terms of studies included or excluded from analysis.